Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodiumglucose cotransporter-2 inhibitors (SGLT2is) both provide cardiovascular benefit, although their clinical profiles differ as SGLT2 inhibitors have shown greater reductions in HF hospitalization, whereas GLP-1 receptor agonists appear particularly effective in reducing atherosclerotic events such as stroke [5, 6]
doi:10.1016/j.jacc.2017.12.015 Khoddam H, Maddah SA, Rezvani Khorshidi S, Zaman Kamkar M, Modanloo M
WHAT TO EXPECT FROM OUR TIRZEPATIDE PROGRAM A streamlined, science-backed plan no guesswork, no gimmicks
Ethics statement Use of human erythrocytes was approved by the La Trobe University Research Ethics Committee (ethics number HEC17013) and an Australian Red Cross Blood Service Agreement (Deed 19-05VIC76 01)
Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al